| Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine DD Von Hoff, T Ervin, FP Arena, EG Chiorean, J Infante, M Moore, T Seay, ... New England Journal of Medicine 369 (18), 1691-1703, 2013 | 6722 | 2013 |
| The consensus molecular subtypes of colorectal cancer J Guinney, R Dienstmann, X Wang, A De Reynies, A Schlicker, ... Nature medicine 21 (11), 1350-1356, 2015 | 4655 | 2015 |
| Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer T André, C Boni, L Mounedji-Boudiaf, M Navarro, J Tabernero, T Hickish, ... New England Journal of Medicine 350 (23), 2343-2351, 2004 | 4475 | 2004 |
| The landscape of somatic copy-number alteration across human cancers R Beroukhim, CH Mermel, D Porter, G Wei, S Raychaudhuri, J Donovan, ... Nature 463 (7283), 899-905, 2010 | 4261 | 2010 |
| ESMO consensus guidelines for the management of patients with metastatic colorectal cancer E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ... Annals of Oncology 27 (8), 1386-1422, 2016 | 3468 | 2016 |
| Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial A Grothey, E Van Cutsem, A Sobrero, S Siena, A Falcone, M Ychou, ... The Lancet 381 (9863), 303-312, 2013 | 3100 | 2013 |
| Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial T André, C Boni, M Navarro, J Tabernero, T Hickish, C Topham, A Bonetti, ... J clin oncol 27 (19), 3109-3116, 2009 | 2750 | 2009 |
| Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer JY Douillard, KS Oliner, S Siena, J Tabernero, R Burkes, M Barugel, ... New England Journal of Medicine 369 (11), 1023-1034, 2013 | 2609 | 2013 |
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective … W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ... The lancet oncology 11 (8), 753-762, 2010 | 2583 | 2010 |
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo … CS Fuchs, J Tomasek, CJ Yong, F Dumitru, R Passalacqua, C Goswami, ... The Lancet 383 (9911), 31-39, 2014 | 2385 | 2014 |
| Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with … JY Douillard, S Siena, J Cassidy, J Tabernero, R Burkes, M Barugel, ... Journal of clinical oncology 28 (31), 4697-4705, 2010 | 2227 | 2010 |
| Genomic analysis identifies association of Fusobacterium with colorectal carcinoma AD Kostic, D Gevers, CS Pedamallu, M Michaud, F Duke, AM Earl, ... Genome research 22 (2), 292-298, 2012 | 2054 | 2012 |
| Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations DM Hyman, I Puzanov, V Subbiah, JE Faris, I Chau, JY Blay, J Wolf, ... New England Journal of Medicine 373 (8), 726-736, 2015 | 1879 | 2015 |
| ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making HJ Schmoll, E Van Cutsem, A Stein, V Valentini, B Glimelius, ... Annals of oncology 23 (10), 2479-2516, 2012 | 1854 | 2012 |
| Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously … E Van Cutsem, J Tabernero, R Lakomy, H Prenen, J Prausová, ... J Clin Oncol 30 (28), 3499-3506, 2012 | 1682 | 2012 |
| Randomized trial of TAS-102 for refractory metastatic colorectal cancer RJ Mayer, E Van Cutsem, A Falcone, T Yoshino, R Garcia-Carbonero, ... New England Journal of Medicine 372 (20), 1909-1919, 2015 | 1423 | 2015 |
| Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ... New England Journal of Medicine 381 (17), 1632-1643, 2019 | 1274 | 2019 |
| Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer S Bullman, CS Pedamallu, E Sicinska, TE Clancy, X Zhang, D Cai, ... Science 358 (6369), 1443-1448, 2017 | 1194 | 2017 |
| Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets PK Brastianos, SL Carter, S Santagata, DP Cahill, A Taylor-Weiner, ... Cancer discovery 5 (11), 1164-1177, 2015 | 1012 | 2015 |
| Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with … J Tabernero, T Yoshino, AL Cohn, R Obermannova, G Bodoky, ... The Lancet Oncology 16 (5), 499-508, 2015 | 999 | 2015 |
